Page 2 - Recursion Pharmaceutical News Today

Canada’s software as a service (SaaS) sector saw a marked year-over-year rebound in investment in 2023, according to a new report from Canadian SaaS accelerator L-Spark.

The company has grabbed plenty of headlines recently.

These two cutting-edge healthcare companies could be significantly undervalued right now.

These two cutting-edge healthcare companies could be significantly undervalued right now.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Ginkgo Bioworks, Recursion Pharmaceutical, and Eli Lilly are cashing in on the AI-Biotech trend…

Wall Street analysts foresee these pre-commercial-stage drugmakers rocketing higher over the next 12 months.

Wall Street analysts foresee these pre-commercial-stage drugmakers rocketing higher over the next 12 months.

Harpoon Therapeutics (NASDAQ:HARP – Free Report) and Recursion Pharmaceuticals (NASDAQ:RXRX – Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, risk, earnings, valuation and institutional ownership. Volatility and Risk Harpoon Therapeutics has a beta of […]

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Rating) – Research analysts at KeyCorp issued their Q1 2024 earnings per share estimates for Recursion Pharmaceuticals in a research report issued to clients and investors on Monday, May 8th. KeyCorp analyst S. Schoenhaus expects that the company will earn ($0.33) per share for the quarter. The consensus estimate […]

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Rating) – Equities researchers at KeyCorp issued their Q1 2024 earnings per share (EPS) estimates for shares of Recursion Pharmaceuticals in a report released on Monday, May 8th. KeyCorp analyst S. Schoenhaus expects that the company will earn ($0.33) per share for the quarter. The consensus estimate for Recursion […]